LUCD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lucid Diagnostics Inc (LUCD) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has shown pre-market gains and has a bullish moving average trend, the company's financials remain weak with negative net income, declining EPS, and gross margin. Additionally, there are no significant trading signals or catalysts to suggest immediate upside potential. A hold is recommended until further positive developments materialize.
The stock shows a bullish moving average trend (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive but contracting, indicating a weakening upward momentum. RSI is neutral at 29.838, and the price is trading near support levels (S1: 1.132). Pre-market price is $1.17, up 7.34%.
Analyst Edward Woo raised the price target to $9, citing high growth potential and Medicare coverage starting. Pre-market price increase of 7.34% indicates short-term positive sentiment.
The company recently announced a direct offering of 18 million shares at $1.00, which could dilute shareholder value. Financial performance remains weak with negative net income, declining EPS, and gross margin.
In Q4 2025, revenue increased by 25.65% YoY to $1,504,000. However, net income remains negative at -$16,266,000, though it improved by 40.94% YoY. EPS dropped by 40% to -0.12, and gross margin declined significantly to -30.65%.
Ascendiant analyst Edward Woo maintains a Buy rating and raised the price target to $9 from $8.25, citing high growth potential driven by Medicare coverage.
